Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 59

1.

Changes in feeding and locomotion induced by amphetamine analogs in rats.

Wellman PJ, Davis KW, Clifford PS, Rothman RB, Blough BE.

Drug Alcohol Depend. 2009 Mar 1;100(3):234-9. doi: 10.1016/j.drugalcdep.2008.10.005. Epub 2008 Dec 4.

2.

Prospects for serotonin 5-HT2R pharmacotherapy in psychostimulant abuse.

Bubar MJ, Cunningham KA.

Prog Brain Res. 2008;172:319-46. doi: 10.1016/S0079-6123(08)00916-3. Review.

PMID:
18772040
3.

Serotonin control of central dopaminergic function: focus on in vivo microdialysis studies.

Di Matteo V, Di Giovanni G, Pierucci M, Esposito E.

Prog Brain Res. 2008;172:7-44. doi: 10.1016/S0079-6123(08)00902-3. Review.

PMID:
18772026
4.

Locomotor stimulation produced by 3,4-methylenedioxymethamphetamine (MDMA) is correlated with dialysate levels of serotonin and dopamine in rat brain.

Baumann MH, Clark RD, Rothman RB.

Pharmacol Biochem Behav. 2008 Aug;90(2):208-17. doi: 10.1016/j.pbb.2008.02.018. Epub 2008 Mar 4.

5.

Monoamine transporters and psychostimulant addiction.

Howell LL, Kimmel HL.

Biochem Pharmacol. 2008 Jan 1;75(1):196-217. Epub 2007 Aug 7. Review.

PMID:
17825265
6.

Faster onset and dopamine transporter selectivity predict stimulant and reinforcing effects of cocaine analogs in squirrel monkeys.

Kimmel HL, O'Connor JA, Carroll FI, Howell LL.

Pharmacol Biochem Behav. 2007 Jan;86(1):45-54. Epub 2006 Dec 20.

7.

Effects of combined dopamine and serotonin transporter inhibitors on cocaine self-administration in rhesus monkeys.

Howell LL, Carroll FI, Votaw JR, Goodman MM, Kimmel HL.

J Pharmacol Exp Ther. 2007 Feb;320(2):757-65. Epub 2006 Nov 14.

9.

Serotonin 5-HT2A and 5-HT2C receptors as potential targets for modulation of psychostimulant use and dependence.

Bubar MJ, Cunningham KA.

Curr Top Med Chem. 2006;6(18):1971-85. Review.

PMID:
17017968
10.

Medication development for addictive disorders: the state of the science.

Vocci FJ, Acri J, Elkashef A.

Am J Psychiatry. 2005 Aug;162(8):1432-40. Review.

PMID:
16055764
11.

Mechanisms of neurotransmitter release by amphetamines: a review.

Sulzer D, Sonders MS, Poulsen NW, Galli A.

Prog Neurobiol. 2005 Apr;75(6):406-33. Review.

PMID:
15955613
12.

Changes in extracellular dopamine during cocaine self-administration in squirrel monkeys.

Kimmel HL, Ginsburg BC, Howell LL.

Synapse. 2005 Jun 1;56(3):129-34.

PMID:
15765537
13.

Development of a rationally designed, low abuse potential, biogenic amine releaser that suppresses cocaine self-administration.

Rothman RB, Blough BE, Woolverton WL, Anderson KG, Negus SS, Mello NK, Roth BL, Baumann MH.

J Pharmacol Exp Ther. 2005 Jun;313(3):1361-9. Epub 2005 Mar 10.

14.

Interaction of cocaine and dopamine transporter inhibitors on behavior and neurochemistry in monkeys.

Ginsburg BC, Kimmel HL, Carroll FI, Goodman MM, Howell LL.

Pharmacol Biochem Behav. 2005 Mar;80(3):481-91.

PMID:
15740791
15.

Relationship between the serotonergic activity and reinforcing effects of a series of amphetamine analogs.

Wee S, Anderson KG, Baumann MH, Rothman RB, Blough BE, Woolverton WL.

J Pharmacol Exp Ther. 2005 May;313(2):848-54. Epub 2005 Jan 26.

16.

Drug addiction: the neurobiology of behaviour gone awry.

Volkow ND, Li TK.

Nat Rev Neurosci. 2004 Dec;5(12):963-70. Review.

PMID:
15550951
17.

The methamphetamine experience: a NIDA partnership.

Hanson GR, Rau KS, Fleckenstein AE.

Neuropharmacology. 2004;47 Suppl 1:92-100. Review.

PMID:
15464128
18.

Agonist-like, replacement pharmacotherapy for stimulant abuse and dependence.

Grabowski J, Shearer J, Merrill J, Negus SS.

Addict Behav. 2004 Sep;29(7):1439-64. Review.

PMID:
15345275
19.

Methamphetamine discrimination and in vivo microdialysis in squirrel monkeys.

Czoty PW, Makriyannis A, Bergman J.

Psychopharmacology (Berl). 2004 Sep;175(2):170-8. Epub 2004 Apr 3.

PMID:
15064912
20.

Supplemental Content

Support Center